Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature

被引：15

作者：

Villamil, Alejandra ^{[1
]}

Mullen, Eduardo ^{[1
]}

Casciato, Paola ^{[1
]}

Gadano, Adrian ^{[1
]}

机构：

[1] Hosp Italiano Buenos Aires, RA-1181 Buenos Aires, DF, Argentina

来源：

ANNALS OF HEPATOLOGY | 2015年 / 14卷 / 02期

关键词：

Autoimmunity; Liver failure; Hepatotoxicity; Early steroid treatment; THYROID-FUNCTION; LIVER-FAILURE; ALPHA-INTERFERON; CONTROLLED-TRIAL; FOLLOW-UP; THERAPY; ASSOCIATION; MULTICENTER; DYSFUNCTION; DISEASES;

D O I：

10.1016/S1665-2681(19)30792-6

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Type I interferons are potent cytokines that possess antiviral, immunomodulating and antiproliferative actions. The development of autoimmune hepatitis is a well recognized complication of treatment with alpha IFN in patients with chronic viral hepatitis. Yet, the occurrence in patients under treatment with beta IFN for other indications is controversial and its occurrence often underestimated. We report two cases of severe acute autoimmune hepatitis in two patients undergoing therapy with IFN beta la for multiple sclerosis who recovered under early immunosuppressive therapy.

引用

页码：273 / 280

页数：8

共 39 条

[1] Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report [J].

Abenavoli, Ludovico ;

Milic, Natasa ;

Beaugrand, Michel .

ANNALS OF HEPATOLOGY, 2013, 12 (01) :152-155

[2] International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].

Alvarez, E ;

Berg, PA ;

Bianchi, FB ;

Bianchi, L ;

Burroughs, AK ;

Cancado, EL ;

Chapman, RW ;

Cooksley, WGE ;

Czaja, AJ ;

Desmet, VJ ;

Donaldson, RT ;

Eddleston, ALWF ;

Fainboim, L ;

Heathcote, J ;

Homberg, JC ;

Hoofnagle, JH ;

Kakumu, S ;

Krawitt, EL ;

Mackay, IR ;

MacSween, RNM ;

Maddrey, WC ;

Manns, MP ;

McFarlane, IG ;

zum Büschenfelde, KHM ;

Mieli-Vergani, G ;

Nakanuma, Y ;

Nishioka, M ;

Penner, E ;

Porta, G ;

Portmann, BC ;

Reed, WD ;

Rodes, J ;

Schalm, SW ;

Scheuer, PJ ;

Schrumpf, E ;

Seki, T ;

Toda, G ;

Tsuji, T ;

Tygstrup, N ;

Vergani, D ;

Zeniya, M .

JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938

[3] Managing the adverse effects of interferon-β therapy in multiple sclerosis [J].

Bayas, A ;

Rieckmann, P .

DRUG SAFETY, 2000, 22 (02) :149-159

[4] Syndromes and complications of interferon therapy [J].

Borg, Frances A. Y. ;

Isenberg, David A. .

CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (01) :61-66

[5] Type I IFNs and their role in the development of autoimmune diseases [J].

Burdick, Laura M. ;

Somani, Najwa ;

Somani, Ally-Khan .

EXPERT OPINION ON DRUG SAFETY, 2009, 8 (04) :459-472

[6]

Byrnes V, 2006, Ann Hepatol, V5, P56

[7] Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-β 1a or 1b therapy:: Predictive factors of thyroid disease development and duration [J].

Caraccio, N ;

Dardano, A ;

Manfredonia, F ;

Manca, L ;

Pasquali, L ;

Iudice, A ;

Murri, L ;

Ferrannini, E ;

Monzani, F .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :4133-4137

[8] Autoimmune hepatitis and multiple sclerosis: a coincidental association? [J].

de Seze, J ;

Canva-Delcambre, V ;

Fajardy, I ;

Delalande, S ;

Stojkovic, T ;

Godet, E ;

Vermersch, P .

MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (06) :691-693

[9]

Duchini A, 2002, AM J GASTROENTEROL, V97, P767

[10]

DUQUETTE P, 1995, NEUROLOGY, V45, P1277

← 1 2 3 4 →